Due to conflicting reports and the paucity of preclinical and clinical data on direct Akt/PDK-1 intervention in AD models, we tested the hypothesis that targeting insulin resistance at this step may be beneficial. The gene discussed is AKT1; the disease is Alzheimer disease.